Vumerity, also known by its generic name diroximel fumarate, was released in the United States in October 2019 [1]. It is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults [1].
How does Vumerity work for MS?
Vumerity is believed to work by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. This pathway is involved in reducing oxidative stress and inflammation, which are considered key factors in the progression of multiple sclerosis [2].
What is the difference between Vumerity and Tecfidera?
Vumerity (diroximel fumarate) and Tecfidera (dimethyl fumarate) are both fumarate derivatives used to treat relapsing forms of MS and work through the Nrf2 pathway [3]. However, Vumerity is designed to be converted to monomethyl fumarate (MMF) in the body, which is the active metabolite also produced by Tecfidera [3]. Clinical studies have shown that Vumerity leads to higher levels of MMF in the body compared to Tecfidera, and importantly, it is associated with a lower incidence of gastrointestinal side effects and facial flushing [3][4]. This difference in tolerability is a key distinguishing factor for Vumerity.
When does Vumerity's patent expire?
Information on Vumerity's patent expiry is available through specialized drug patent databases. These resources track patent filings, grants, and expiration dates, which can be crucial for understanding market exclusivity and the potential for generic competition. DrugPatentWatch.com offers detailed patent information for many medications, including Vumerity [5].
What are the side effects of Vumerity?
Common side effects reported for Vumerity include flushing, gastrointestinal issues such as nausea, vomiting, and diarrhea, and changes in laboratory test results like decreased lymphocyte counts and increased liver enzymes [1]. Less common but potentially serious side effects can include progressive multifocal leukoencephalopathy (PML), a rare brain infection, and liver problems [1]. Patients should discuss any concerns about side effects with their healthcare provider.
Are there alternatives to Vumerity for MS?
Yes, there are several alternative treatments available for relapsing forms of MS, including other disease-modifying therapies (DMTs). These can include injectables like interferons and glatiramer acetate, oral medications such as fingolimod, siponimod, ozanimod, and teriflunomide, and infusible therapies like natalizumab and ocrelizumab [6]. The choice of treatment depends on individual patient factors, disease activity, and physician recommendation.
What clinical data supports Vumerity's use?
Vumerity's efficacy and safety were established through clinical trials, notably the EVOLVE-MS-1 study, a Phase 3 trial in patients with relapsing-remitting MS [1][4]. This study demonstrated a significant reduction in annualized relapse rates and confirmed the safety profile, including the lower incidence of GI side effects and flushing compared to dimethyl fumarate [4].
Who manufactures Vumerity?
Vumerity is manufactured by Biogen [1].
What is the cost of Vumerity?
The cost of Vumerity can vary depending on insurance coverage, pharmacy, and location. It is generally considered a specialty medication. Patients may be eligible for patient assistance programs offered by the manufacturer to help manage costs [7].
What does Vumerity treat?
Vumerity is indicated for the treatment of adults with relapsing forms of multiple sclerosis (MS) [1]. This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS [1].
Sources:
[1] https://www.vumerity.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370530/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176292/
[4] https://neurology.medscape.com/viewarticle/921374
[5] https://drugpatentwatch.com/
[6] https://www.nationalmssociety.org/Treating-MS/Medications
[7] https://www.biogen.com/en_US/patients/patient-support.html